Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus BioSciences is positioned as a leader in the global biosimilar marketplace. Coherus BioSciences commercializes UDENYCAÂŽ (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCAÂŽ in the European Union. Coherus BioSciences is advancing two late-stage clinical products towards commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. Source
No articles found.
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
Private Health Management was founded in 2007 after Leslie D. Michelson and Gregg ...
Private Health Management was founded in 2007 a...
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
Join the National Investor Network and get the latest information with your interests in mind.